With the ongoing progress of basic research along with the introduction of new pharmaceutical options spanning almost all therapeutic areas, the need for biomarkers that will be implemented into the personalized medical approach is higher than ever. Their use can be incorporated into clinical practice and can be applied to the classification of disorders and the evaluation of disease severity but also to the monitoring of the progress of therapeutic/pharmaceutical interventions. This systematic review collects the findings of hematologic biomarkers in various cutaneous malignancies, excluding malignant melanoma, to support their potential use in the prognosis but also in the assessment of therapeutic strategies for the specific category of skin disorders.
随着基础研究的持续进展以及几乎所有治疗领域新药物方案的引入，对能够融入个体化医疗的生物标志物的需求比以往任何时候都更为迫切。这些生物标志物可整合至临床实践中，不仅可用于疾病分类与病情严重程度评估，还能用于监测治疗/药物干预的进展。本系统性综述汇总了除恶性黑色素瘤外各类皮肤恶性肿瘤中血液学标志物的研究结果，旨在支持其在该类特定皮肤疾病的预后评估及治疗策略制定中的潜在应用价值。
肿瘤(癌症)患者之家